{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-007758","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.351232+00:00","generated_at":"2026-05-30T03:24:40.086862+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sunshine Biopharma Q3 2024 revenues up 42% YoY; net loss widens 84% in quarter","bullets":["Q3 2024 gross revenues $8.44M, up 42% from $5.96M in Q3 2023; YTD revenues $25.28M, up 54%.","Q3 net loss $(1.20M) compared to $(0.65M) in Q3 2023, a YoY increase of 84%.","YTD net loss $(2.98M) vs $(3.26M) in prior year period, an improvement of 9%.","Shareholders' equity grew 18% to $25.04M from $21.21M at Dec 31, 2023.","Growth driven by new product launches and expanded marketing via Canadian subsidiary Nora Pharma."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-007758","json":"https://secwatch.observer/filing/0001683168-24-007758.json","markdown":"https://secwatch.observer/filing/0001683168-24-007758.md","text":"https://secwatch.observer/filing/0001683168-24-007758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824007758/0001683168-24-007758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824007758/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:24:40.086862+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}